5[3]James EFR. Martindale Pharmacopoeia. 31st edition[M]. London: The Royal Pharmaceutical Society，1996:388.
6[5]Rapeport WG， Mendelo AD， French G， et al. Plasma protein binding and CSF concentration of valproic acid in man following acute oral drug[J]. Br J Clin Pharmac，1983，16:356.
7Novelli G, Margiord K, Sangiuolo F, et al. Pharmacogenetics of human andraogens and prostatic diseases. Pharmacogcnomics,2001,2(1) :65.
8Sim E, Payton M, Noble M, et al. An update on genetic, structural and functional studies of arylamine N - acetyltransferases in euearyotes and procaryotes J. Hum Mol Genet, 2000, 9 ( 16 ) :2435.
9March R. Pharmacogenomics: the genomics of drug response.Yeast, 2000. 17 (1) : 16.
10Hamet P. Genes and hypertension: where we are and where we should do. Clin Exp Hypertens, 1999,21(5 -6) : 947.
